United Therapeutics Corporation (BMV:UTHR)
Mexico
· Delayed Price · Currency is MXN | Market Cap | 431.91B |
| Revenue (ttm) | 57.30B |
| Net Income (ttm) | 24.03B |
| Shares Out | n/a |
| EPS (ttm) | 501.57 |
| PE Ratio | 17.97 |
| Forward PE | 18.32 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 44 |
| Average Volume | 501 |
| Open | 9,643.95 |
| Previous Close | 8,062.17 |
| Day's Range | 9,643.95 - 9,643.95 |
| 52-Week Range | 5,672.39 - 9,643.95 |
| Beta | n/a |
| RSI | n/a |
| Earnings Date | May 6, 2026 |
About United Therapeutics
United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. It offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Nebulized Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of tre... [Read more]
Financial Performance
In 2025, United Therapeutics's revenue was $3.18 billion, an increase of 10.61% compared to the previous year's $2.88 billion. Earnings were $1.33 billion, an increase of 11.68%.
Financial numbers in USDNews
United Therapeutics Corporation to Report First Quarter 2026 Financial Results Before Market Open on Wednesday, May 6, 2026
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its first quarter 2026 financial results in a pre...
United Therapeutics Corporation Presents New Data Spanning Pulmonary Hypertension Treatment, Lung Donor Expansion, and Xenotransplantation at ISHLT 2026
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that 11 new data presentations across ...
United Therapeutics Receives FDA Regenerative Medicine Advanced Therapy Designation for miroliverELAP® for Treatment of Acute Liver Failure
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that the U.S. Food and Drug Administra...
United Therapeutics Corporation Announces TETON-1 Pivotal Study of Tyvaso® Meets Primary Endpoint for Treatment of Idiopathic Pulmonary Fibrosis, Exceeding Impressive Treatment Effect Seen in TETON-2
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that its TETON-1 study evaluating the ...
United Therapeutics Corporation Announces Full Results of TETON-2 Phase 3 Clinical Trial Published in The New England Journal of Medicine
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that the New England Journal of Medici...
United Therapeutics Transcript: Leerink Global Healthcare Conference 2026
Recent clinical trial successes position Tyvaso and ralinepag as leading therapies for pulmonary diseases, with rapid commercialization and significant revenue growth expected. The pipeline features innovative inhalers and organ manufacturing advances, while AI-driven models are streamlining drug development.
United Therapeutics Corporation Announces $2 Billion Stock Repurchase Authorization and Enters into $1.5 Billion Accelerated Share Repurchase Program
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that the company's Board of Directors ...
United Therapeutics Corporation to Present at the Leerink Global Healthcare Conference
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR) announced today that Dr. Martine Rothblatt, Chairperson and Chief Executive Officer, ...
United Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference
Strong double-digit growth is expected to continue, driven by robust Ralinepag data and new inhaled therapies. Ralinepag is projected to become a blockbuster, while Tyvaso's expansion into IPF and other indications offers significant market opportunities. Xenotransplantation and disciplined capital allocation further support long-term growth.
United Therapeutics Transcript: Study result
The Phase III ADVANCE OUTCOMES trial showed ralinepag significantly reduced clinical worsening in PAH patients, with robust efficacy across all subgroups and a favorable safety profile. Its once-daily dosing and tolerability position it as a potential frontline therapy, likely to expand the oral prostacyclin market.
United Therapeutics' blood pressure drug meets main, secondary goals in late-stage study
United Therapeutics said on Monday its experimental pill for a type of blood pressure disorder met all the main and secondary goals of a late-stage study.
United Therapeutics Corporation Announces Ralinepag Achieved 55% Reduction in Risk of Clinical Worsening in Pivotal Pulmonary Arterial Hypertension Study, Delivering Exceptional, Highly Statistically Significant Efficacy
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that its long-term pivotal phase 3 ADV...
These Analysts Increase Their Forecasts On United Therapeutics After Upbeat Q4 Earnings
United Therapeutics Corp (NASDAQ: UTHR) reported better-than-expected earnings for the fourth quarter on Wednesday.
United Therapeutics Earnings Call Transcript: Q4 2025
Record 2025 revenue surpassed $3B, driven by Tyvaso and Orenitram, with double-digit growth expected to continue. Three transformative product launches are planned by 2027, and a $4B run rate is targeted, excluding new launches.
United Therapeutics Corporation Reports Fourth Quarter and Full Year 2025 Financial Results
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ...
United Therapeutics Corporation to Present at the TD Cowen 46th Annual Health Care Conference
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR) announced today that Michael Benkowitz, President and Chief Operating Officer, will p...
United Therapeutics Corporation to Report Fourth Quarter and Full Year 2025 Financial Results Before the Market Opens on Wednesday, February 25, 2026
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its fourth quarter and full year 2025 financial r...
United Therapeutics Announces Positive Results from Phase 1 Study of miroliverELAP® in Patients with Acute Liver Failure
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR) today announced positive results from its phase 1 study of miroliverELAP®, an externa...
United Therapeutics Corporation Announces Appointment of Kevin J. Tracey to its Board of Directors
SILVER SPRING, Md. & DURHAM, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that the company's Board of Directors appointed Kevin ...
United Therapeutics Transcript: 44th Annual J.P. Morgan Healthcare Conference
IPF and super-prostacyclin are set to drive major growth, with Tyvaso showing game-changing results in IPF and ralinepag poised to lead in pulmonary hypertension. Expansion into orphan oncology and xenotransplantation further strengthens the pipeline.
United Therapeutics Corporation to Present at the 44th Annual J.P. Morgan Healthcare Conference
SILVER SPRING, Md. & DURHAM, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR) announced today that Dr. Martine Rothblatt, Chairperson and Chief Executive Officer, will present a c...
Flurry of Bullish Inflows Sends United Therapeutics Higher
United Therapeutics Corporation (UTHR) shares up 3,603% since Big Money first bought big in 2004.
United Therapeutics Transcript: Jefferies London Healthcare Conference 2025
Tyvaso and Tyvaso DPI drive robust growth, with resilience against new competitors and a $1B quarterly revenue run rate targeted by 2027. Strong IPF data and a broad pipeline, including organ transplantation, support long-term expansion.
United Therapeutics Transcript: UBS Global Healthcare Conference 2025
Strong double-digit growth in Tyvaso, best-in-class IPF trial results, and pipeline progress underpin confidence in reaching a $4B revenue run rate by 2027. Xenotransplantation program achieved a first-in-human milestone, with further updates expected after initial cohort completion.